Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy

被引：0
|
作者：
Boormans, J. L. [1 ]
De Jong, J. J. [1 ]
Liu, V. Y. T. [2 ]
Bismar, T. A. [3 ]
Boorjian, S. A. [4 ]
Huang, H-C. [2 ]
Davicioni, E. [5 ]
Mian, O. Y. [6 ]
Wright, J. L. [7 ]
Necchi, A. [8 ]
Dall'Era, M. [9 ]
Kaimakliotis, H. Z. [10 ]
Black, P. C. [11 ]
Gibb, E. A. [2 ]
Lotan, Y. [12 ]
机构：
[1] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[2] Decipher Biosci, Dept Res, Vancouver, BC, Canada
[3] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada
[4] Mayo Clin, Dept Urol, Rochester, MN USA
[5] Decipher Biosci, Dept Res, San Diego, CA USA
[6] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA
[7] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[8] Univ Vita Salute San Raffaele, Dept Med, Milan, Italy
[9] Univ Calif Davis, Dept Urol Surg, Davis, CA 95616 USA
[10] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
[11] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[12] Univ Texas Southwestern, Dept Urol, Dallas, TX USA
来源：
EUROPEAN UROLOGY | 2021年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P0830
引用
收藏
页码：S1156 / S1156
页数：1
相关论文
共 50 条
  • [1] LUMINAL PRIMARY MUSCLE-INVASIVE BLADDER CANCER PATIENTS ARE LESS LIKELY TO BENEFIT FROM PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY
    Lotan, Yair
    de Jong, Joep
    Liu, Vinnie
    Bismar, Tarek
    Boorjian, Stephen
    Huang, Huei-Chung
    Davicioni, Elai
    Mian, Omar
    Wright, Jonathan
    Necchi, Andrea
    Dall'Era, Marc
    Kaimakliotis, Hristos
    Black, Peter
    Gibb, Ewan
    Boormans, Joost
    JOURNAL OF UROLOGY, 2021, 206 : E908 - E908
  • [2] Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
    Lotan, Yair
    de Jong, Joep J.
    Liu, Vinnie Y. T.
    Bismar, Tarek A.
    Boorjian, Stephen A.
    Huang, Huei-Chung
    Davicioni, Elai
    Mian, Omar Y.
    Wright, Jonathan L.
    Necchi, Andrea
    Dall'Era, Marc A.
    Kaimakliotis, Hristos Z.
    Black, Peter C.
    Gibb, Ewan A.
    Boormans, Joost L.
    JOURNAL OF UROLOGY, 2022, 207 (03): : 541 - 550
  • [3] Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?
    Niegisch, Guenter
    Lorch, Anja
    Droller, Michael J.
    Lavery, Hugh J.
    Stensland, Kristian D.
    Albers, Peter
    EUROPEAN UROLOGY, 2013, 64 (03) : 355 - 357
  • [4] Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy
    Wang, Ziwei
    He, Wei
    Ying, Yidie
    Wang, Maoyu
    Chen, Qing
    Zhang, Zhensheng
    Zeng, Shuxiong
    Xu, Chuanliang
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 201 - 209.e7
  • [5] Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer
    Liew, Mun Sem
    Au-Yeung, George
    Davis, Ian D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 101 - 102
  • [6] Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
    Rimar, Kalen J.
    Glaser, Alexander P.
    Kundu, Shilajit
    Schaeffer, Edward M.
    Meeks, Joshua
    Psutka, Sarah P.
    BLADDER CANCER, 2018, 4 (04) : 411 - 418
  • [7] Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer
    Leibowitz-Amit, R.
    Israel, A.
    Gal, M.
    Atenafu, E. A.
    Symon, Z.
    Portnoy, O.
    Laufer, M.
    Dotan, Z.
    Ramon, J.
    Avni, D.
    Fridman, E.
    Berger, R.
    CLINICAL ONCOLOGY, 2016, 28 (12) : 790 - 796
  • [8] Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
    Calabro, Fabio
    Sternberg, Cora N.
    EUROPEAN UROLOGY, 2009, 55 (02) : 348 - 358
  • [9] Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis
    Shimizu, Fumitaka
    Muto, Satoru
    Taguri, Masataka
    Ieda, Takeshi
    Tsujimura, Akira
    Sakamoto, Yoshiro
    Fujita, Kazuhiko
    Okegawa, Takatsugu
    Yamaguchi, Raizo
    Horie, Shigeo
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (05) : 367 - 372
  • [10] Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
    Guancial, Elizabeth A.
    Kilari, Deepak
    Xiao, Guang-Qian
    Abu-Farsakh, Sohaib H.
    Baran, Andrea
    Messing, Edward M.
    Kim, Eric S.
    PLOS ONE, 2016, 11 (05):
12345